Select Language:
Boehringer Ingelheim announced that the German pharmaceutical company will begin manufacturing its flagship diabetes medication, Trajenta, at its Shanghai facility, with plans to start deliveries in the Chinese market by 2028.
Locally producing Trajenta, an oral medication that helps regulate blood sugar levels by stimulating insulin production, aims to improve supply stability, broaden patient access, and drive upgrades and expansion of equipment at the Shanghai plant. The company revealed this plan today.
Sales of Trajenta have been consistently increasing worldwide, reaching €1.7 billion (approximately $1.96 billion) in 2023, according to company data.
This initiative aligns with the company’s 30th anniversary in China. Mohammed Tawil, the president and CEO of its China operations, highlighted that China has become a key market and innovation center for the business. He emphasized that the company intends to continue harnessing China’s rapid development, scale, and influence to localize its research and development efforts and better serve patients globally.
Earlier this year, the company disclosed plans to invest over CNY 5 billion (around $701 million) in China over the next five years to develop new products. Its human health research will focus on areas such as metabolism, inflammation, eye health, and cancer, while its animal health unit will accelerate vaccine innovation and development.
Boehringer Ingelheim employs more than 3,700 people across China and maintains a major regional hub in Shanghai. The Shanghai facility serves as the company’s China headquarters and hosts research and development, digital laboratories, and a large biopharmaceutical production complex. The site handles human pharmaceuticals, animal health products, and contract manufacturing for biopharmaceuticals.
ChatGPT
Perplexity
Gemini AI
Grok AI
